Lead Product(s) : Ranolazine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Receives FDA Approval for Ranolazine ER Tablets 500mg and 1000m
Details : Ranolazine is a specific inhibitor of late sodium current, reduces sodium overload and hence ameliorates disturbed ion homeostasis. This is associated with symptomatic improvement of angina in patients.
Product Name : Ranexa-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Ranolazine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
